Total Neoadjuvant Treatment
Phase 2Small molecule
Total Neoadjuvant Treatment is one of 28 small molecule programs targeting Neoadjuvant Treatment. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
27
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
27 competitors in Neoadjuvant Treatment
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Abraxane
Bristol-Myers SquibbPhase 3
Paraplatin
AAvyxa
Phase 3
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Taxotere
AAvyxa
Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Phase 3
Adrucil
EElorac, Inc.
Phase 3
Eloxatin
TevaPhase 2
Perjeta
RochePhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Neoadjuvant Treatment1 trial
Chemotherapy Combined With Adebrelimab and Mecapegfilgrastim in Neoadjuvant Treatment of Potentially Resectable BTC
Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06037655·30 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Total Neoadjuvant Treatment. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details